Bespoke Extracts (BSPK) Cash from Financing Activities (2011 - 2025)
Bespoke Extracts (BSPK) reported Cash from Financing Activities of $35000.0 for Q3 2025, up 40.0% on a YoY basis from $25000.0 in Q3 2024, and up 1650.0% sequentially from $2000.0 in Q2 2025.
Bespoke Extracts (BSPK) Cash from Financing Activities (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 14 years of Cash from Financing Activities data on file, last reported at $35000.0 in Q3 2025.
- For the quarter ending Q3 2025, Cash from Financing Activities rose 40.0% year-over-year to $35000.0; the trailing twelve-month figure through Sep 2025 stood at $255000.0 (up 30.85% YoY), and the FY2024 full-year result was $343500.0, down 13.56% from the prior year.
- Cash from Financing Activities climbed to $35000.0 in Q3 2025, from $2000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $600000.0 in Q1 2021 to a low of -$8957.0 in Q3 2023.
- A 5-year average of $152286.1 and a median of $126099.5 in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities tumbled 105.6% in 2023 and soared 563.51% in 2024, its largest moves.
- Tracing BSPK's Cash from Financing Activities over 5 years: stood at $25000.0 in 2021, then jumped by 922.01% to $255502.0 in 2022, then slumped by 89.68% to $26375.0 in 2023, then soared by 563.51% to $175000.0 in 2024, then plunged by 80.0% to $35000.0 in 2025.
- Business Quant data shows BSPK's Cash from Financing Activities at $35000.0 in Q3 2025, $2000.0 in Q2 2025, and $43000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | 35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 35,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 175,000.00 |
| Dec 31, 2024 | 175,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 38,500.00 |
| Jun 30, 2024 | 38,500.00 |
| Mar 31, 2024 | 105,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | 26,375.00 |
| Dec 31, 2023 | 26,375.00 |
| Sep 30, 2023 | -8,957.00 |
| Sep 30, 2023 | -8,957.00 |
| Jun 30, 2023 | 192,954.00 |
| Jun 30, 2023 | 192,954.00 |